Table 2 Age at treatment initiation and long-term GH treatment outcomes in children born SGA

Dahlgren 2005 [36]

77

Ob/prepubertal to FH

Prepubertal during >2 years GH therapy vs prepubertal during <2 years GH therapy

Mean gain FH SDS prepubertal for >2 years GH therapy = 1.7; prepubertal for <2 years = 0.9

<0.001

de Ridder 2008 [47]

150

Data from 2 previous GH trials; R, DB/5 years[38]; R, C/3 years[48]

Median age 7.5/Statistical model predicting HSDS at puberty

Age at start (−0.27 estimated coefficient)Other significant predictors: HSDS at start (0.71 estimated coefficient), target height SDS (0.13 estimated coefficient), GH dose X IGF-I SDS at start (−0.29 estimated coefficient), gender (−0.34 estimated coefficient)

<0.0001 = 0.009 to <0.0001

Ranke 2010 [45]

161

KIGS, clinical trials/7.7 years

Median age 7.8 years/Statistical models predicting AH SDS and ∆HSDS

70% of variability in adult height SDS: HSDS at GH start, ∆HSDS 1st year on GH, years on treatment [younger start, longer phase], maternal HSDS, length SDS at birth, SRS diagnosis

NR

60% of variability in ∆HSDS: ∆HSDS 1st year GH, H-MPH SDS at GH start, years of GH treatment [younger start, longer phase]

van Pareren 2003 [37]

54

MC, R, DB/mean 7.8 years

Mean age 8.1/∆HSDS correlations

∆HSDS from start of GH treatment to AH negatively correlated with age at treatment start: r = −0.36

<0.01